Evidence Synthesis
Jubilpharma sees its 64.98% gross margin accelerate to its highest quarterly reading since 5.41% in 2025, up from 5.41% in the prior quarter.
Loading stock analysis…
Loading stock analysis…
Evidence Synthesis
Last synthesized: 5 Sept 2026, 01:27
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence Synthesis
Jubilpharma sees its 64.98% gross margin accelerate to its highest quarterly reading since 5.41% in 2025, up from 5.41% in the prior quarter.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 64.98 % | 5.41 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 5.41 % | 4.09 | ▲ |
| REVENUE_GROWTH_YOY | 17.3 % | -45 | ▲ |
| EPS_ACTUAL | 7.845 INR | 5.014 | ▲ |
| EPS_SURPRISE_PERCENT | 0.105 % | -0.273 | ▲ |
| PRICE_CHANGE_PERCENT | 1.828 % | — | - |
| DAILY_VOLUME | 4,98,118 shares | 1,98,361 | ▲ |
| CLOSE_PRICE | 924.5 INR | 907.9 | ▲ |
| NEWS_SENTIMENT_SCORE | 0 score | — | - |
| ANALYST_STRONG_BUY_COUNT | 0 count | 1 | ▼ |
| TARGET_PRICE_PREMIUM | 17.74 % | — | - |